The Food and Drug Administration on Monday approved Culver City-based ImmunityBio’s treatment for bladder cancer.
The U.S. health regulator on Monday approved ImmunityBio's combination therapy to treat a type of bladder cancer, marking an ...
A California-based immunotherapy company with local operations received good news this week that the U.S. Food and Drug Administration has approved its bladder cancer treatment drug. ImmunityBio Inc.
Autoimmune Disorders: Bristol Myers Squibb has entered into a research agreement with Repertoire to develop vaccines for ...
The Food and Drug Administration has approved a new treatment for patients with bladder cancer that does not respond well to standard therapy. The treatment, which will be sold under the brand ...
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the ...
X4 Pharmaceuticals said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in ...
The Food and Drug Administration ... bladder cancer, according to an FDA statement announcing the approval. News of the FDA action was first reported by Reuters, which said, "The therapy works by ...
The U.S. Food and Drug Administration (FDA ... available for BCG-unresponsive non–muscle-invasive bladder cancer. "The FDA approval of N-803 heralds a new era in the management of BCG ...
Labcorp’s diagnostic assay will act as a companion diagnostic for Pfizer’s recently approved haemophilia B gene therapy ...
The drug is combined with the BCG vaccine, mainly used against tuberculosis and as a common treatment for some forms of bladder cancer. Last year in May, the FDA issued a complete response letter ...
(Reuters) -The U.S. health regulator approved on Monday ImmunityBio's combination therapy to treat a type of bladder cancer ... the U.S. Food and Drug Administration (FDA) declined clearance ...